Business Update
Genencor sells its therapeutic vaccine program in multimillion dollar deal
Published in Vaccine Weekly, April 28th, 2004
Innogenetics will develop and commercialize current product candidates in Genencor's vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor. Genencor will recognize license fees in the first year totaling $10 million, and will receive further payments of up to $87 million as development milestones are achieved.
Genencor will also receive royalty payments on product sales. Genencor plans to apply the funds from this transaction...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2004-04-28)
More Articles from Vaccine Weekly
- Influenza Vaccine
Influenza vaccination changes lymphocyte distribution in tonsils - Malaria Vaccine
Antibodies to malaria peptide mimics inhibit invasion of erythrocytes - Meningococcal Vaccine
Mimics of capsular polysaccharide protect against group B meningococci - Shigellosis Vaccine
Shigella flexneri 2a vaccine protects against shigellosis symptoms - Tuberculosis Vaccine
Mycobacterium bovis BCG plus novel adjuvant protects against tuberculosis - AIDS/HIV Vaccine
Finding epitopes of HIV-1 that induce protective antibodies remains a challenge - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
